Clinical Trials Logo

Encephalomyelitis, Equine clinical trials

View clinical trials related to Encephalomyelitis, Equine.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04131595 Completed - Equine Encephalitis Clinical Trials

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

Start date: October 7, 2019
Phase: Phase 1
Study type: Interventional

To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.

NCT ID: NCT03879603 Completed - Clinical trials for Eastern Equine Encephalitis

VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults

Start date: April 2, 2019
Phase: Phase 1
Study type: Interventional

Western Equine Encephalitis Virus (WEEV), Eastern Equine Encephalitis Virus (EEEV), and Venezuelan Equine Encephalitis Virus (VEEV) are transmitted to humans by infected mosquitoes and can cause encephalitis (swelling of the brain) and other neurological manifestations, including fever, chills, discomfort, feeling sick, muscle pain and then headache, vomiting, restlessness, irritability, seizures, coma, and death. Vaccines teach the body to prevent or fight an infection. When the body learns to fight an infection, this is called an immune response. Researchers developed a vaccine against Western, Eastern and Venezuelan equine encephalitis viruses to help the body make an immune response. There are no live or killed viruses in the vaccine, so you cannot get infected with any of these 3 viruses from getting the vaccine. The experimental trivalent encephalitis vaccine, VRC-WEVVLP073-00-VP, is composed of Western equine encephalitis (WEE), Eastern equine encephalitis (EEE), and Venezuelan equine encephalitis (VEE) virus-like particles (VLP). The purpose of this study is to test three doses (6 mcg, 30 mcg, and 60 mcg) of this experimental vaccine against Western, Eastern and Venezuelan equine encephalitis viruses.

NCT ID: NCT02654509 Completed - Clinical trials for Eastern Equine Encephalitis

Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine

Start date: June 3, 2008
Phase: Phase 2
Study type: Interventional

This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine.

NCT ID: NCT01984983 Completed - Clinical trials for Venezuelan Equine Encephalitis Virus Infection

Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers

Start date: December 2013
Phase: Phase 1
Study type: Interventional

The Phase I study will assess the basic safety, tolerability, and immunogenicity of a DNA-based Venezuelan equine encephalitis virus (VEEV)vaccine candidate delivered by electroporation . The study will enroll 40 healthy adult volunteers ages 18-49 and will comprise evaluation of intradermal or intramuscular administration by electroporation. Administration of the vaccine candidate will be at two DNA dose levels (0.5 mg/ml and 2.0 mg/ml) for each route of administration. Electroporation will be administered using the TriGrid Delivery System devices for intramuscular and intradermal delivery. An additional group of subjects will serve as a placebo control, receiving injections of saline with electroporation. The overall goal of this study will be to determine if further human clinical studies of the vaccine candidate are warranted and, if so, to aid in the selection of dose and route of administration for future studies.

NCT ID: NCT01159561 Completed - Virus Clinical Trials

Western Equine Encephalitis Vaccine, Inactivated

WEE
Start date: February 2010
Phase: Phase 1
Study type: Interventional

This study is designed to determine the safety and immunogenicity of WEE Vaccine Lot number 3-1-92.

NCT ID: NCT00584805 Completed - Clinical trials for Eastern Equine Encephalitis

Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine

EEE
Start date: June 3, 2008
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of Eastern Equine Encephalitis (EEE) Vaccine.